{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dementia/prescribing-information/lorazepam/","result":{"pageContext":{"chapter":{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam","depth":2,"htmlHeader":"<!-- begin field ee8c4e19-cf70-4d1d-b8a5-8411b1787436 --><h2>Lorazepam</h2><!-- end field ee8c4e19-cf70-4d1d-b8a5-8411b1787436 -->","summary":"","htmlStringContent":"<!-- begin item db751296-b1d2-4fe9-9cb5-940e0cfdfc0d --><!-- begin field 15319f4e-6507-45d0-9a4c-138f2a626a3c --><ul><li><strong>Lorazepam should only be used on the advice of a specialist for the treatment of challenging behaviour associated with dementia.</strong><ul><li>Short-term treatment with lorazepam (off-label use) may be suggested for immediate management of violence, aggression, or extreme agitation in people with dementia when non-pharmacological measures have failed and the person poses a risk to themselves or others.</li><li>The aim of the treatment is to calm the person and reduce agitation or aggression, not to sedate.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE Pathway, 2016</a>]</p><!-- end field 15319f4e-6507-45d0-9a4c-138f2a626a3c --><!-- end item db751296-b1d2-4fe9-9cb5-940e0cfdfc0d -->","topic":{"id":"de9cbb4d-2d69-500f-be27-dc83f76dc3ba","topicId":"2491e3e7-cc21-42b9-8972-e54804b4782f","topicName":"Dementia","slug":"dementia","lastRevised":"Last revised in October 2020","chapters":[{"id":"af834011-0042-530a-8f9a-acd5828e0a34","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0360b83-4555-5079-897f-12b2d555c1af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes"},{"id":"7ced1224-30c2-5f30-9caf-3764f3665ae4","slug":"update","fullItemName":"Update"}]},{"id":"fae05cff-ad98-52fa-89b4-b97369195d59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2f3b4bd3-e7cf-5492-afe0-0a5b230eab7e","slug":"goals","fullItemName":"Goals"},{"id":"9104785e-e491-5ca3-b3d3-7e951385bce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a9c56eb4-bc0e-51cc-b486-a54c23906bc0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebf62eba-a4cd-536c-8c9f-c9505b0e7482","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a71b8dc2-79f8-5d24-b668-c792abc5a624","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c87232ba-6926-5ff2-98d2-f8839b0c0d37","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46c6316f-eec0-580a-80ec-2112d2f0122f","slug":"definition","fullItemName":"Definition"},{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes"},{"id":"87101d89-6073-57cc-b247-48be586ef185","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"58f6ec5a-c90b-5e64-a476-fc9fca39c6ae","slug":"prevalence","fullItemName":"Prevalence"},{"id":"994469e3-f824-5f48-b755-7f74dd360680","slug":"prognosis","fullItemName":"Prognosis"},{"id":"718f9ed4-d725-5f6e-a86f-5df88719cd52","slug":"complications","fullItemName":"Complications"}]},{"id":"366bcbe3-827a-5e08-9d81-8de84e46fefd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"565bac2a-ada3-5b0a-ab7d-6681501b2c4a","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"4c0fe55f-40c9-5a1c-8cf3-1ec8d88406d5","slug":"assessment","fullItemName":"Assessment"},{"id":"ef7780bd-8e94-5f95-870f-92ab930c4365","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","fullItemName":"Management","slug":"management","subChapters":[{"id":"c6c0cbc2-18fc-5bf8-973d-bc38b9001f28","slug":"suspected-dementia","fullItemName":"Scenario: Suspected dementia"},{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care"},{"id":"343a59fa-439e-5ab9-9d3b-28a893d55d2f","slug":"management-of-end-stage-dementia","fullItemName":"Scenario: Management of end-stage dementia"}]},{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors"},{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride"}]},{"id":"1e87c908-2ab5-5cba-8d6a-958c03f7a6cd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fc7a2bcf-854b-5ca4-9b02-2dcaaebe1162","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7bcb26a3-cc69-5201-9fd9-6353e27b412f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c383917-58d0-5036-8217-5d9fd81cb2cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fdb8af52-aeee-52bd-be79-c5534939d42f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a9f930f3-f8b6-5c8f-b8ca-b3155e0c23d3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"668c11fa-1873-58d4-b0e2-3eab90e8fbff","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67c4aef9-fbf4-5bf6-8dc5-c501f74b1fe3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e416d218-9694-5e92-8a57-9b1b43ac40ad","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field bb3c3c2a-ee7a-437c-aaeb-5e71be578074 --><h3>What dose of lorazepam is usually prescribed?</h3><!-- end field bb3c3c2a-ee7a-437c-aaeb-5e71be578074 -->","summary":"","htmlStringContent":"<!-- begin item 97ab7bfb-2c53-4a1b-a8e3-9fc8a3f5614e --><!-- begin field 48ac30ca-90f0-4301-8a15-df53744d7d77 --><ul><li><strong>Lorazepam (off-label) for the treatment of challenging behaviour associated with dementia should <em>only</em> be used on the advice of a specialist who should specify dose and duration of treatment. </strong>As a general guide:<ul><li>Treatment should start at the lowest possible dose (0.5 mg) orally and be titrated slowly in increments, if necessary, to a maximum of 1 mg daily (2 mg daily in exceptional circumstances). </li><li>The maximum daily dose of 1 mg (2 mg daily in exceptional circumstances) is extrapolated from the British National Formulary (BNF), which recommends a dose range of 1–4 mg (or 0.5 mg–2 mg for elderly or debilitated people) in daily divided doses for the treatment of anxiety [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>].</li></ul></li><li>One-to-one care of the person should be available while the dose is titrated in a controlled and safe manner.</li><li>The person should be reviewed regularly and lorazepam discontinued as soon as possible.<ul><li>If parenteral treatment is being considered, admission is recommended because the person will need to be monitored closely after administration. This is due to the risk of respiratory arrest following parenteral administration of lorazepam [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015b</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE Pathway, 2016</a>]</p><!-- end field 48ac30ca-90f0-4301-8a15-df53744d7d77 --><!-- end item 97ab7bfb-2c53-4a1b-a8e3-9fc8a3f5614e -->","subChapters":[]},{"id":"9784db88-c6f9-5f20-acc6-e62101fc260a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field baac7339-fb2d-4926-ad5b-9080fdc44d5d --><h3>What are the adverse effects of lorazepam?</h3><!-- end field baac7339-fb2d-4926-ad5b-9080fdc44d5d -->","summary":"","htmlStringContent":"<!-- begin item c039277c-2315-42ad-bd9d-fe0e4a20c6eb --><!-- begin field ae841b89-dca8-4575-9cef-f9e599aca20a --><ul><li><strong>The most frequently reported adverse effects of benzodiazepines (such as lorazepam) include:</strong><ul><li>Daytime drowsiness.</li><li>Dizziness.</li><li>Muscle weakness.</li><li>Ataxia.</li></ul></li><li><strong>Less commonly reported adverse effects include:</strong><ul><li>Blood and lymphatic system disorders, such as thrombocytopenia, leucopenia, agranulocytosis, and pancytopenia.</li><li>Immune system disorders, such as hypersensitivity reactions (including anaphylaxis/anaphylactoid reactions).</li><li>Endocrine disorders, such as the syndrome of inappropriate antidiuresis (SIAD) and, hyponatraemia.</li><li>Psychiatric disorders, such as confusion (especially in the elderly), depression, numbed emotions, disinhibition, euphoria, dependence, and suicidal ideation or attempt. </li><li>Paradoxical reactions, such as restlessness, agitation, irritability, aggressiveness, delusion, rage, insomnia, nightmares, hallucinations, psychoses, sexual arousal, and inappropriate behaviour.</li><li>Disorders of the central nervous system, such as light-headedness, sedation, headache, reduced alertness, dysarthria/slurred speech, transient anterograde amnesia or memory impairment, tremor, extrapyramidal reactions, and coma.</li><li>Eye disorders such as diplopia, and blurred vision.</li><li>Vascular disorders, such as hypotension.</li><li>Respiratory and mediastinal disorders, such as apnoea, worsening of sleep apnoea, worsening of obstructive pulmonary disease, and respiratory depression.</li><li>Gastrointestinal disorders, such as nausea, constipation, and salivation changes.</li><li>Hepatobiliary disorders, such as abnormal liver function tests (increases in bilirubin, transaminases, and alkaline phosphatase) and jaundice.</li><li>Skin disorders, such as rashes and allergic dermatitis.</li><li>Reproductive system disorders, such as erectile dysfunction.</li><li>General symptoms, such as asthenia, fatigue, and hypothermia.</li><li>Drug withdrawal symptoms, such as headache, muscle pain, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, and 'rebound' symptoms.</li></ul></li><li><strong>Advise people taking benzodiazepines who intend to drive that</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Department for Transport, 2014</a>]<strong>:</strong><ul><li>They should not drive if they feel drowsy, dizzy, or unable to concentrate or make decisions. </li><li>It is now an offence to drive if they have more than a specified amount of benzodiazepine in their body, whether driving is impaired or not.<ul><li>Roadside drug screening tests have been introduced to the UK since March 2015. These test the saliva for drugs that impair driving, such as benzodiazepines. </li><li>If the person has a positive roadside drug test for benzodiazepines, the police may ask them to provide a blood sample to measure the amount of benzodiazepine in their body.</li><li>If they are found to have more than the specified amount of benzodiazepine but their driving is not impaired, and they are taking the drug on the advice of their GP or pharmacist, they will be able to raise a 'statutory defence' and the police may not prosecute them.</li><li>It may be helpful for the person to keep evidence with them while they are driving to show that they are taking a benzodiazepine in accordance with medical advice).</li><li>Suitable evidence may include the medication box with the pharmacy label on, or the other half of the prescription with the list of drugs prescribed by the doctor. </li></ul></li><li>An information leaflet on '<a href=\"https://assets.publishing.service.gov.uk/media/54730806e5274a130300002f/con437439.pdf\" target=\"\" data-hyperlink-id=\"4cb8ccb0-1e14-4e24-b697-a8f7014a9f7d\">New law on driving having taken certain drugs</a>'  is available at <a href=\"http://www.gov.uk/\" data-hyperlink-id=\"865a2820-ce11-4735-a4bd-a8f7014a9f99\">www.gov.uk</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field ae841b89-dca8-4575-9cef-f9e599aca20a --><!-- end item c039277c-2315-42ad-bd9d-fe0e4a20c6eb -->","subChapters":[]},{"id":"7a8e2450-e067-580f-803f-5596253310c0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0458183b-5406-4935-a077-d5f1c73e63b2 --><h3>What are the contraindications and cautions with lorazepam?</h3><!-- end field 0458183b-5406-4935-a077-d5f1c73e63b2 -->","summary":"","htmlStringContent":"<!-- begin item 29982eb7-6e45-47dd-ada8-73eb316f9728 --><!-- begin field db13320e-8a42-4e1f-a87e-e744bdb20b2d --><ul><li><strong>Do not prescribe lorazepam:</strong></li><ul><li><strong>If a person has (or is suspected of having):</strong></li><ul><li>Hypersensitivity to benzodiazepines or to any of the other excipients used in the formulation. This includes people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.</li><li>Respiratory depression, marked neuromuscular respiratory weakness (including myasthenia gravis), acute pulmonary insufficiency, or sleep apnoea syndrome.</li><li>Chronic psychosis or, phobic or obsessional states.</li><li>Severe hepatic impairment (may precipitate encephalopathy).</li><li>Hyperkinesis.</li><li>Depression (with or without anxiety) — benzodiazepines should not be used alone in this group of people, as they may precipitate suicide.</li></ul><li>In pregnant women.</li></ul><li><strong>Prescribe lorazepam with caution in people who:</strong><br></li><ul><li>Are frail or elderly.</li><li>Are hypotensive — benzodiazepines should be used with caution where a drop in blood pressure might lead to cardiovascular or cerebrovascular complications. This is particularly important in elderly people.</li><li>Have acute narrow-angle glaucoma.</li><li>Have impaired renal function.</li><li>Have mild to moderate hepatic impairment.</li><li>Have chronic respiratory insufficiency.</li><li>Have taken alcohol or other central nervous system depressants.</li><li>Have a history of drug or alcohol dependence.</li><li>Have organic brain changes.</li><li>Have a personality disorder (such as dependent, avoidant, or obsessive-compulsive) — may increase risk of dependence. </li></ul></ul>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<br><!-- end field db13320e-8a42-4e1f-a87e-e744bdb20b2d --><!-- end item 29982eb7-6e45-47dd-ada8-73eb316f9728 -->","subChapters":[]},{"id":"406ab75c-637d-501f-94e2-7ecd19c6b49c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field dd33b856-98f6-42e2-b112-6f145ebfb5bf --><h3>What drug interactions can occur with lorazepam?</h3><!-- end field dd33b856-98f6-42e2-b112-6f145ebfb5bf -->","summary":"","htmlStringContent":"<!-- begin item 82ba4b57-2345-41e1-8356-90d017511540 --><!-- begin field 6cf4f9dc-c01d-4a3f-89cd-fa94f469ef71 --><ul><li><strong>Lorazepam may interact with:</strong><ul><li><strong>Alcohol</strong> — advise that lorazepam should not be used together with alcohol due to enhanced sedative effects and impaired ability to drive or operate machinery.</li><li><strong>Antacids</strong> — concurrent use may delay the absorption of lorazepam.</li><li><strong>Antiepileptic drugs</strong> — both reduction and elevation of drug levels have been reported. Phenobarbital taken concomitantly may result in an additive central nervous system (CNS) effect. Valproate may increase plasma concentration of lorazepam.</li><li><strong>Antihypertensives, vasodilators, and diuretics</strong> — enhanced hypotensive effect may occur during concurrent treatment with angiotensin-converting enzyme (ACE) inhibitors, alpha-blockers, angiotensin-II receptor antagonists (AIIRAs), calcium-channel blockers, adrenergic neurone blockers, beta-blockers, moxonidine, nitrates, hydralazine, minoxidil, sodium nitroprusside, and diuretics. Enhanced sedative effects may occur with alpha-blockers or moxonidine.</li><li><strong>Antiretrovirals</strong> —  there is an increased risk of prolonged sedation with concurrent use. In addition, zidovudine clearance is increased by lorazepam. Avoid concurrent use.</li><li><strong>Caffeine </strong>— concurrent use may result in reduced sedative and anxiolytic effects of lorazepam.</li><li><strong>Centrally-acting drugs</strong> — central depressive effect may be enhanced if lorazepam is combined with drugs such as neuroleptics, antipsychotics, antidepressants, hypnotics, analgesics, anaesthetics, barbiturates, and sedative antihistamines. Elderly people may require special supervision.</li><li><strong>Clozapine </strong>— serious adverse effects (such as marked sedation, hypotension, ataxia, delirium, and respiratory arrest) have been reported when clozapine is given concurrently with lorazepam.</li><li><strong>Dopaminergics</strong> — lorazepam may antagonize the effects of levodopa.</li><li><strong>Drugs that affect hepatic enzymes </strong>(particularly cyctochrome P450):<ul><li>Liver enzyme inducers (for example rifampicin) may increase clearance of benzodiazepines. </li><li>Liver enzyme inhibitors (for example cimetidine, isoniazid, erythromycin, omeprazole, and esomeprazole) reduce the clearance (and may potentiate the action) of benzodiazepines. Itraconazole, ketoconazole, and to a lesser extent, fluconazole and voriconazole are potent inhibitors of the cytochrome P450 isoenzyme CYP3A4 and may increase plasma levels of benzodiazepines. The effects of benzodiazepines may be increased and prolonged by concomitant use. A dose reduction of the benzodiazepine may be required.</li></ul></li><li><strong>Drugs that enhance sedation</strong> — there is an increased sedative effect when lorazepam is given with drugs such as cisapride, lofexidine, nabilone, sodium oxybate, disulfiram, baclofen, and tizanidine. Avoid concomitant use.</li><li><strong>Grapefruit juice</strong> — inhibition of CYP3A4 by grapefruit juice may increase the plasma concentration of lorazepam, leading to possible increased sedation and amnesia. This interaction may be of little significance in healthy people, but factors such as old age or liver cirrhosis may increase the risk of adverse effects with concurrent use.</li><li><strong>Opiate analgesics</strong> — enhancement of euphoria following concurrent treatment with an opiate and lorazepam may lead to increased psychological dependence.</li><li><strong>Theophylline/aminophylline </strong>— concurrent use may result in increased metabolism of lorazepam, which possibly reduces its effect.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field 6cf4f9dc-c01d-4a3f-89cd-fa94f469ef71 --><!-- end item 82ba4b57-2345-41e1-8356-90d017511540 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}